FDA-APPROVED GLP-1 TREATMENT OPTIONS
Access brand-name, FDA-approved GLP-1 treatment options through licensed medical providers, with transparent all-inclusive pricing and ongoing care.
Licensed medical providers · Brand-name medications · No hidden fees
Licensed Provider Evaluation
FDA-Approved Brand-Name Options
All-Inclusive Self-Pay Pricing
Treatment options span weight management, type 2 diabetes and related metabolic health needs. Your licensed provider will determine which treatment, if any, is medically appropriate for you.
Zepbound®
Tirzepatide
Weight Management + OSA
$1,375/month
All-inclusive self-pay price
Learn About Zepbound
Wegovy®
Semaglutide
Weight + Metabolic Health
$1,741/month
All-inclusive self-pay price
Learn About Wegovy
Mounjaro®
Tirzepatide
Type 2 Diabetes + Cardiovascular Health
$1,375/month
All-inclusive self-pay price
Learn About Mounjaro
Ozempic®
Semaglutide
Type 2 Diabetes + Cardiovascular & Kidney Health
$1,255/month
All-inclusive self-pay price
Learn About Ozempic
These prescription medications have important risks and are not appropriate for everyone. Zepbound, Wegovy, Mounjaro and Ozempic carry boxed warnings regarding the risk of thyroid C-cell tumors observed in rodents. It is unknown whether these medications cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.
These medications are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Additional warnings, precautions and contraindications vary by medication.
Your licensed provider will review your medical history and current medications before determining whether treatment is appropriate.
View Important Safety Information
01
Health history
02
Treatment goals
03
Existing conditions
04
Medication history
05
Provider evaluation
HOW VITARIA CARE WORKS
01
Complete Online Evaluation
Answer a few questions about your health, goals and medical history.
02
Provider Review
A licensed provider reviews your information to determine what may be appropriate for you.
03
Personalized Plan
If appropriate, you’ll receive a personalized treatment plan with transparent, all-inclusive pricing.
04
Ongoing Care
Get your medication, when prescribed, with ongoing support from your medical team.
Your monthly self-pay price includes Vitaria Care services, provider care, prescribed medication, pharmacy fulfillment and shipping.
Licensed provider care
Medication when prescribed
Pharmacy fulfillment
Shipping
Ongoing Vitaria Care support
Prices shown are current self-pay prices available through participating pharmacies in the available pharmacy network and may change. Prescription medication is provided only when prescribed following medical evaluation.
01 / 04
Zepbound® (tirzepatide) is a once-weekly injectable prescription medication. Tirzepatide acts on receptors for two naturally occurring hormones involved in metabolic regulation: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).
FDA-approved uses
Zepbound is FDA-approved, together with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight who have at least one weight-related condition.
It is also FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
How it works
Tirzepatide activates GIP and GLP-1 receptors. These pathways are involved in appetite, food intake and metabolic regulation. Treatment is used together with appropriate nutrition and physical activity as directed by the prescribing clinician.
Important considerations
Zepbound is a prescription medication and is not appropriate for everyone. A licensed provider will review your health history, medications, treatment goals and relevant contraindications before determining whether treatment is appropriate.
Do not use Zepbound together with another tirzepatide-containing product or with a GLP-1 receptor agonist.
A licensed provider will determine which treatment options may be appropriate for you.
02 / 04
What it is
Wegovy® injection (semaglutide) is a once-weekly injectable prescription medication. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
FDA-approved uses
Wegovy is FDA-approved, together with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight who have at least one weight-related condition, and in certain pediatric patients with obesity.
Wegovy is also FDA-approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.
Wegovy injection is additionally FDA-approved for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis in adults. This indication was granted under accelerated approval.
How it works
Semaglutide activates GLP-1 receptors. GLP-1 pathways are involved in appetite, calorie intake, glucose regulation and other metabolic processes.
Important considerations
Wegovy is a prescription medication and is not appropriate for everyone. A licensed provider will review your health history, medications and treatment goals before determining whether treatment is appropriate.
Do not use Wegovy with other semaglutide-containing products or other GLP-1 receptor agonists.
A licensed provider will determine which treatment options may be appropriate for you.
03 / 04
What it is
Mounjaro® (tirzepatide) is a once-weekly injectable prescription medication. Tirzepatide activates GIP and GLP-1 receptors.
FDA-approved uses
Mounjaro is FDA-approved, together with diet and exercise, to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
Mounjaro is also FDA-approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events.
Mounjaro is not FDA-approved for chronic weight management.
How it works
Tirzepatide activates GIP and GLP-1 receptors. These pathways influence glucose-dependent insulin secretion, glucagon concentrations, gastric emptying and other aspects of metabolic regulation.
Important considerations
Mounjaro is a prescription medication and is not appropriate for everyone. A licensed provider will determine whether its FDA-approved indications and safety profile are appropriate for the individual patient.
A licensed provider will determine which treatment options may be appropriate for you.
04 / 04
What it is
Ozempic® (semaglutide) is a once-weekly injectable prescription medication used in adults with type 2 diabetes. Semaglutide is a GLP-1 receptor agonist.
FDA-approved uses
Ozempic is FDA-approved, together with diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.
It is also FDA-approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
Ozempic is additionally FDA-approved to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
Ozempic is not FDA-approved for chronic weight management.
How it works
Semaglutide activates GLP-1 receptors. Its effects include glucose-dependent stimulation of insulin secretion, reduction of glucagon secretion and delayed gastric emptying.
Important considerations
Ozempic is a prescription medication and is not appropriate for everyone. A licensed provider will review the patient’s medical history, medications and treatment goals before determining whether treatment is appropriate.
A licensed provider will determine which treatment options may be appropriate for you.
Our Providers
Medical Team
Experienced practitioners supporting your personal weight-management goals.
IMPORTANT SAFETY INFORMATION
Zepbound® Important Safety Information
Zepbound® (tirzepatide) has a boxed warning about the risk of thyroid C-cell tumors. In studies in rats, tirzepatide caused thyroid C-cell tumors. It is not known whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.
Do not use Zepbound if you or a family member have had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of its ingredients.
Zepbound may cause serious side effects, including severe gastrointestinal reactions, acute kidney injury due to volume depletion, gallbladder problems, acute pancreatitis, serious allergic reactions, low blood sugar, particularly when used with insulin or certain diabetes medicines, and diabetic retinopathy complications in patients with type 2 diabetes. Zepbound delays gastric emptying, and rare cases of pulmonary aspiration have been reported in patients receiving GLP-1-based medicines during procedures requiring general anesthesia or deep sedation. Tell your healthcare team that you take Zepbound before planned surgery or procedures.
Zepbound is not recommended in patients with severe gastroparesis. Tell your healthcare provider if you are pregnant, plan to become pregnant, or take other prescription or over-the-counter medicines.
The most common adverse reactions reported with Zepbound include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss and gastroesophageal reflux disease.
Zepbound contains tirzepatide. Use with another tirzepatide-containing product or a GLP-1 receptor agonist is not recommended.
See Full Prescribing InformationWegovy® Injection Important Safety Information
Wegovy® (semaglutide) has a boxed warning about the risk of thyroid C-cell tumors. In studies in rodents, semaglutide caused thyroid C-cell tumors. It is not known whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.
Do not use Wegovy if you or a family member have had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Wegovy if you have had a serious allergic reaction to semaglutide or any of its ingredients.
Wegovy may cause serious side effects, including acute pancreatitis, gallbladder problems, low blood sugar, acute kidney injury due to volume depletion, severe gastrointestinal reactions, serious allergic reactions, diabetic retinopathy complications in patients with type 2 diabetes and increased heart rate. Wegovy delays gastric emptying, and pulmonary aspiration has been reported in patients receiving GLP-1 receptor agonists during procedures requiring general anesthesia or deep sedation. Tell your healthcare team that you take Wegovy before planned surgery or procedures.
Wegovy is not recommended in patients with severe gastroparesis.
For cardiovascular risk reduction or weight reduction, Wegovy should be discontinued when pregnancy is recognized. Tell your healthcare provider if you are pregnant, plan to become pregnant or take other prescription or over-the-counter medicines.
Common adverse reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, abdominal distension, belching, flatulence, gastroesophageal reflux disease and hair loss. Other common adverse reactions identified in the prescribing information may occur.
Wegovy contains semaglutide and should not be used with another semaglutide-containing product or another GLP-1 receptor agonist.
See Full Prescribing InformationMounjaro® Important Safety Information
Mounjaro® (tirzepatide) has a boxed warning about the risk of thyroid C-cell tumors. In studies in rats, tirzepatide caused thyroid C-cell tumors. It is not known whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.
Do not use Mounjaro if you or a family member have had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Mounjaro if you have had a serious allergic reaction to tirzepatide or any of its ingredients.
Mounjaro may cause serious side effects, including acute pancreatitis, low blood sugar when used with insulin or certain diabetes medicines, serious allergic reactions, acute kidney injury due to volume depletion, severe gastrointestinal reactions, diabetic retinopathy complications in patients with a history of diabetic retinopathy and gallbladder problems. Mounjaro delays gastric emptying, and pulmonary aspiration has been reported in patients receiving GLP-1 receptor agonists during procedures requiring general anesthesia or deep sedation. Tell your healthcare team that you take Mounjaro before planned surgery or procedures.
Mounjaro is not recommended in patients with severe gastroparesis.
Mounjaro may affect absorption of oral medicines. Patients using oral hormonal contraceptives should discuss contraception with their provider because the prescribing information recommends switching to a non-oral contraceptive method or adding a barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.
Tell your healthcare provider if you are pregnant, plan to become pregnant or take other prescription or over-the-counter medicines.
The most common adverse reactions reported with Mounjaro are nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and abdominal pain.
See Full Prescribing InformationOzempic® Important Safety Information
Ozempic® (semaglutide) has a boxed warning about the risk of thyroid C-cell tumors. In studies in rodents, semaglutide caused thyroid C-cell tumors. It is not known whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.
Do not use Ozempic if you or a family member have had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Ozempic if you have had a serious allergic reaction to semaglutide or any of its ingredients.
Ozempic may cause serious side effects, including acute pancreatitis, diabetic retinopathy complications, low blood sugar when used with insulin or certain diabetes medicines, acute kidney injury due to volume depletion, severe gastrointestinal reactions, serious allergic reactions and gallbladder problems. Ozempic delays gastric emptying, and pulmonary aspiration has been reported in patients receiving GLP-1 receptor agonists during procedures requiring general anesthesia or deep sedation. Tell your healthcare team that you take Ozempic before planned surgery or procedures.
Ozempic is not recommended in patients with severe gastroparesis.
Tell your healthcare provider if you are pregnant or plan to become pregnant. The prescribing information recommends discontinuing Ozempic at least 2 months before a planned pregnancy.
The most common adverse reactions reported with Ozempic are nausea, vomiting, diarrhea, abdominal pain and constipation.
See Full Prescribing InformationVitaria Care is an independent healthcare service and is not affiliated with, sponsored by, or endorsed by Eli Lilly and Company or Novo Nordisk. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S.
What are FDA-approved GLP-1 medications?
GLP-1-based medications are prescription treatments that act on metabolic pathways involved in glucose regulation, appetite and other processes. Semaglutide acts on the GLP-1 receptor, while tirzepatide acts on both GIP and GLP-1 receptors. FDA-approved uses differ by medication, so your provider will determine whether a particular treatment is appropriate for your health needs.
Are all four medications approved for weight loss?
No. Zepbound and Wegovy have FDA-approved indications for chronic weight management in eligible patients. Mounjaro and Ozempic are FDA-approved for type 2 diabetes and have additional FDA-approved indications in specified populations, but they are not FDA-approved for chronic weight management. Your provider determines which medication, if any, is medically appropriate.
How does my provider determine which treatment is appropriate?
Your provider reviews factors including your medical history, current medications, treatment goals, existing health conditions and the FDA-approved indications and safety profile of each medication. A specific medication is prescribed only when the provider determines that it is medically appropriate.
What does the monthly price include?
The listed self-pay price includes Vitaria Care services, provider care, prescribed medication, pharmacy fulfillment and shipping. There are no hidden fees. Prices may change based on pharmacy pricing and availability.
Do I need insurance?
No. The prices shown on this page are self-pay prices, so insurance is not required. Vitaria Care does not submit these treatment-plan charges to insurance.
Are these compounded medications?
No. The treatments described on this page are FDA-approved brand-name medications. They are different from compounded semaglutide or compounded tirzepatide.
Can everyone take a GLP-1 medication?
No. GLP-1-based medications are not appropriate for everyone and each medication has specific contraindications, warnings and precautions. A licensed provider must evaluate your medical history and current medications before determining whether treatment is appropriate.
Complete your online evaluation to see which treatment options may be appropriate for your health needs.
